CR20210627A - Derivados de benzisoxazol sulfonimada - Google Patents

Derivados de benzisoxazol sulfonimada

Info

Publication number
CR20210627A
CR20210627A CR20210627A CR20210627A CR20210627A CR 20210627 A CR20210627 A CR 20210627A CR 20210627 A CR20210627 A CR 20210627A CR 20210627 A CR20210627 A CR 20210627A CR 20210627 A CR20210627 A CR 20210627A
Authority
CR
Costa Rica
Prior art keywords
sup
compounds
sulfonamide derivatives
patients
treatment
Prior art date
Application number
CR20210627A
Other languages
English (en)
Inventor
Ylva Elisabet Bergman Bozikis
Paul Francis Richardson
Samantha Elizabeth Greasley
Robert Arnold Kumpf
Scott Channing Sutton
Oleg Brodsky
Paul Anthony Stupple
Michelle Ang Camerino
Pei-Pei Kung
Robert Louis Hoffman
Original Assignee
Pfizer
Ctxt Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer, Ctxt Pty Ltd filed Critical Pfizer
Publication of CR20210627A publication Critical patent/CR20210627A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La presente invención se relaciona con los compuestos de la fórmula (I), o sales farmacéuticamente aceptables de los mismos, en donde el Anillo A, R1-R8, y n se definen en la presente. Los derivados de benzisoxazol sulfonamida novedosos son útiles para el tratamiento de crecimiento celular anormal, tal como cáncer, en pacientes. Las modalidades adicionales relacionadas con las composiciones farmacéuticas que contienen los compuestos y a métodos de utilización los compuestos y composiciones en el tratamiento de crecimiento celular anormal en pacientes.
CR20210627A 2019-06-18 2020-06-16 Derivados de benzisoxazol sulfonimada CR20210627A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962863199P 2019-06-18 2019-06-18
US201962953223P 2019-12-24 2019-12-24
US202063025278P 2020-05-15 2020-05-15
PCT/IB2020/055589 WO2020254946A1 (en) 2019-06-18 2020-06-16 Benzisoxazole sulfonamide derivatives

Publications (1)

Publication Number Publication Date
CR20210627A true CR20210627A (es) 2022-02-08

Family

ID=71738189

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210627A CR20210627A (es) 2019-06-18 2020-06-16 Derivados de benzisoxazol sulfonimada

Country Status (29)

Country Link
US (2) US11492346B2 (es)
EP (2) EP4299135A3 (es)
JP (2) JP7352662B2 (es)
KR (1) KR20220024671A (es)
CN (1) CN114364672B (es)
AU (2) AU2020296361A1 (es)
BR (1) BR112021025528A2 (es)
CA (1) CA3143666C (es)
CL (1) CL2021003372A1 (es)
CO (1) CO2021017504A2 (es)
CR (1) CR20210627A (es)
DK (1) DK3986890T3 (es)
EC (1) ECSP21091615A (es)
ES (1) ES2969616T3 (es)
FI (1) FI3986890T3 (es)
HR (1) HRP20231501T1 (es)
HU (1) HUE064683T2 (es)
IL (1) IL288802A (es)
LT (1) LT3986890T (es)
MD (1) MD3986890T2 (es)
MX (1) MX2021016085A (es)
PE (1) PE20220808A1 (es)
PL (1) PL3986890T3 (es)
PT (1) PT3986890T (es)
RS (1) RS64931B1 (es)
SI (1) SI3986890T1 (es)
TW (1) TWI787620B (es)
UY (1) UY38752A (es)
WO (1) WO2020254946A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201810092D0 (en) * 2018-06-20 2018-08-08 Ctxt Pty Ltd Compounds
JP2022534425A (ja) 2019-05-31 2022-07-29 イケナ オンコロジー， インコーポレイテッド Ｔｅａｄ阻害剤およびその使用
MD3986890T2 (ro) 2019-06-18 2024-04-30 Pfizer Derivați de benzizoxazolsulfonamide
EP4181920A1 (en) * 2020-07-15 2023-05-24 Pfizer Inc. Kat6 inhibitor methods and combinations for cancer treatment
WO2022187693A1 (en) * 2021-03-05 2022-09-09 Umbra Therapeutics Inc. Covalent cdk2-binding compounds for therapeutic purposes
WO2022187688A1 (en) * 2021-03-05 2022-09-09 Umbra Therapeutics Inc. Covalent kras-binding compounds for therapeutic purposes
MX2023013683A (es) * 2021-05-21 2024-02-23 Aurigene Oncology Ltd Compuestos de isoxazolilo fusionados como inhibidores de lisina acetiltransferasa 6a (kat6a).
EP4368620A1 (en) 2021-07-05 2024-05-15 Hangzhou Innogate Pharma Co., Ltd. Compound serving as kat6 inhibitor
AU2022325367A1 (en) 2021-08-10 2024-02-08 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Sulfonamide derivative, preparation method therefor and medical use thereof
PE20241355A1 (es) 2021-11-16 2024-07-03 Insilico Medicine Ip Ltd Inhibidores de lisina acetiltransferasa 6a (kat6a) y usos de los mismos
WO2023114710A1 (en) * 2021-12-13 2023-06-22 Aurigene Oncology Limited Fused benzoisoxazolyl compounds as kat6a inhibitors
WO2023192817A1 (en) * 2022-03-28 2023-10-05 Isosterix, Inc. Inhibitors of the myst family of lysine acetyl transferases
US20230416240A1 (en) * 2022-06-16 2023-12-28 Prelude Therapeutics Incorporated Kat6 targeting compounds
WO2024023703A1 (en) 2022-07-29 2024-02-01 Pfizer Inc. Dosing regimens comprising a kat6 inhibitor for the treatment of cancer
WO2024131772A1 (zh) * 2022-12-20 2024-06-27 杭州中美华东制药有限公司 具有sting抑制作用的含肟化合物及其药物组合物和用途
WO2024165035A1 (zh) * 2023-02-10 2024-08-15 江苏恒瑞医药股份有限公司 一种磺酰胺衍生物结晶形式及其制备方法
WO2024199254A1 (zh) * 2023-03-27 2024-10-03 北京康辰药业股份有限公司 磺酰胺化合物、其药物组合物和应用
WO2024201334A1 (en) 2023-03-30 2024-10-03 Pfizer Inc. Kat6a as a predictive biomarker for treatment with a kat6a inhibitor and methods of treatment thereof

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3064003A (en) 1962-11-13 Carboxylic acid derivatives of sub-
US2358031A (en) 1944-09-12 Substituted thiadiazoles
US2525321A (en) 1949-01-07 1950-10-10 American Cyanamid Co Hydroxybenzenesulfonamidoisoxazoles and preparation of same
GB689281A (en) 1950-02-18 1953-03-25 Lunbeck Corp Improvements in or relating to the production of sulphanilamido-thiadiazoles
DE1102745B (de) 1959-06-06 1961-03-23 Boehringer & Soehne Gmbh Verfahren zur Herstellung von 5-Sulfanilamidoisoxazolen
BE617370A (fr) 1961-05-09 1962-11-08 Ciba Geigy Procédé de préparation du 2,5-di-[benzoxazolyl-(2')]-thiofène
US3332942A (en) 1962-11-02 1967-07-25 White Lab Inc Substituted thiadiazoles
JPS498255B1 (es) 1970-10-08 1974-02-25
US3951967A (en) 1972-03-20 1976-04-20 Merck & Co., Inc. 7-Mercapto(or thio)-benzothiadiazine products
US3960854A (en) 1972-03-20 1976-06-01 Merck & Co., Inc. 7-Mercapto(or thio)-benzothiadiazine products
DE2617809C2 (de) 1976-04-23 1984-09-20 Basf Ag, 6700 Ludwigshafen Verfahren zur Stabilisierung von Chromdioxid-Magnetpigmenten und seine Verwendung
JPS6042794B2 (ja) 1977-09-27 1985-09-25 三共株式会社 イソオキサゾリウム塩，およびその製造方法
US4251664A (en) 1978-05-24 1981-02-17 Henkel Corporation Sulfonamidothiadiazoles, metal complexes thereof, and solutions containing such compounds for use in extraction of metal values
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
JPS603685B2 (ja) 1980-04-15 1985-01-30 日本コロムビア株式会社 絵入りレコ−ド盤の製造方法
GB8427618D0 (en) 1984-11-01 1984-12-05 Shell Int Research Anticoccidial compositions
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
JPS63238006A (ja) 1987-03-26 1988-10-04 Shionogi & Co Ltd イモチ防除剤
US5591761A (en) 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5962490A (en) 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
NZ231534A (en) 1988-11-29 1992-02-25 Warner Lambert Co 3,5-di-t-butyl-4-hydroxyphenyl-triazoles, oxadiazoles and thiadiazoles; anti-inflammatory compositions
JPH03258771A (ja) 1990-03-09 1991-11-19 Tosoh Corp スルホンアミド誘導体、その製法及びそれを有効成分として含有する除草剤
TW224462B (es) 1992-02-24 1994-06-01 Squibb & Sons Inc
FR2690160A1 (fr) 1992-04-15 1993-10-22 Rhone Poulenc Rorer Sa Application de dérivés d'acide 2H-1,2,4-benzothiadiazine-1,1-dioxyde-3-carboxylique à la préparation de médicaments, les produits nouveaux, leur préparation et les médicaments les contenant.
NZ247440A (en) 1992-05-06 1995-04-27 Squibb & Sons Inc Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof
FI941826A (fi) 1993-04-21 1994-10-22 Takeda Chemical Industries Ltd Menetelmät ja koostumukset elimen hypofunktion ennaltaehkäisemiseksi ja/tai terapeuttiseksi hoitamiseksi
JP3901229B2 (ja) 1994-05-13 2007-04-04 Ｎｔｎ株式会社 耐熱・潤滑性樹脂組成物
ATE243203T1 (de) 1995-04-04 2003-07-15 Texas Biotechnology Corp Thienyl-, furyl-, pyrrolyl- und biphenylsulfonamide und derivate zur modulation der endothelin-aktivität
US5804585A (en) 1996-04-15 1998-09-08 Texas Biotechnology Corporation Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
JP2002514192A (ja) 1996-11-13 2002-05-14 セフアロン・インコーポレーテツド ベンゾチアゾおよび関連の複素環基を含有するシステインおよびセリンプロテアーゼ阻害剤
JP3455233B2 (ja) 1997-04-28 2003-10-14 テキサス・バイオテクノロジー・コーポレイシヨン エンドテリン介在障害治療用のスルホンアミド類
US5783705A (en) 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
NZ517828A (en) 1999-09-17 2003-10-31 Millennium Pharm Inc Inhibitors having activity against mammalian factor Xa
AU2456701A (en) 1999-12-31 2001-07-16 Texas Biotechnology Corporation Pharmaceutical and veterinary uses of endothelin antagonists
EP1259485B1 (en) 2000-02-29 2005-11-30 Millennium Pharmaceuticals, Inc. BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa
GB0127344D0 (en) 2001-11-14 2002-01-02 Cancer Res Ventures Ltd Assay method
EP1461327A1 (en) 2001-11-22 2004-09-29 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
JP2003292485A (ja) 2002-04-01 2003-10-15 Yamanouchi Pharmaceut Co Ltd スルホンアミド誘導体
AR043633A1 (es) 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides
EP1631558A1 (en) 2003-05-21 2006-03-08 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type i
WO2004113310A1 (en) 2003-06-25 2004-12-29 Biovitrum Ab Use of an inhibitor of 11-b-hydroxysteroid dehydrogenase type 1 compounds for promoting wound healing
US7326788B2 (en) 2003-07-22 2008-02-05 Janssen Pharmaceutica N.V. Quinolinone derivatives as inhibitors of c-fms kinase
US7615563B2 (en) 2003-08-08 2009-11-10 Gonzalez Iii Jesus E Compositions useful as inhibitors of voltage-gated sodium channels
EP2332912A1 (en) 2003-08-08 2011-06-15 Vertex Pharmaceuticals Incorporated Heteroarylaminosulfonylphenylderivates for use as sodium or calcium channel blockers in the treatment of pain
US7642260B2 (en) 2003-11-13 2010-01-05 Abbott Laboratories, Inc. Apoptosis promoters
US7767684B2 (en) 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
US7973161B2 (en) 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US8614318B2 (en) 2003-11-13 2013-12-24 Abbvie Inc. Apoptosis promoters
MX2007004526A (es) 2004-10-12 2007-09-21 Decode Genetics Inc Arilsulfonamidas biciclicas peri-sustituidas para la enfermedad arterial oclusiva.
WO2006124744A1 (en) 2005-05-16 2006-11-23 Vertex Pharmaceuticals Incorporated Bicyclic derivatives as modulators of ion channels
DE102005038947A1 (de) 2005-05-18 2006-11-30 Grünenthal GmbH Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln
KR20080050607A (ko) 2005-10-06 2008-06-09 사노피-아벤티스 바이사이클릭 아릴-설폰산[1,3,4]-티아디아졸-2-일-아미드, 이의 제조방법 및약제로서의 이의 용도
AU2006299089A1 (en) 2005-10-06 2007-04-12 Sanofi-Aventis N-[1 ,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals
DE102005055355A1 (de) 2005-11-21 2007-10-31 Merck Patent Gmbh 3,6-Dihydro-2-oxo-6H-[1,3,4]thiadiazinderivate
RU2008129821A (ru) 2005-12-21 2010-01-27 Вертекс Фармасьютикалз Инкорпорейтед (Us) Гетероциклические производные в качестве модуляторов ионных каналов
EP2420494B1 (en) 2006-08-16 2014-10-08 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Use of thiadiazole compounds as inhibitors of kynurenine-3-monooxygenase
WO2008064116A2 (en) 2006-11-16 2008-05-29 Abbott Laboratories Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
AU2007321920A1 (en) 2006-11-20 2008-05-29 Alantos Pharmaceuticals Holding, Inc. Heterotricyclic metalloprotease inhibitors
US20080194557A1 (en) 2007-01-18 2008-08-14 Joseph Barbosa Methods and compositions for the treatment of pain, inflammation and cancer
JP5460589B2 (ja) 2007-07-13 2014-04-02 アイカジェン， インコーポレイテッド ナトリウムチャネル阻害物質
JP2011502984A (ja) 2007-11-01 2011-01-27 サートリス ファーマシューティカルズ， インコーポレイテッド サーチュインモジュレーターとしてのアミド誘導体
WO2009086303A2 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
EP2240474B1 (en) 2007-12-26 2012-03-14 Sanofi Cyclic pyridyl-n-(1,3,4)-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals
JP5774989B2 (ja) 2008-08-13 2015-09-09 スメド−ティーエイ／ティーディー・エルエルシー 整形外科用ねじ
WO2010046780A2 (en) 2008-10-22 2010-04-29 Institut Pasteur Korea Anti viral compounds
CN102438988B (zh) 2009-04-21 2015-06-24 内尔维阿诺医学科学有限公司 作为hsp90抑制剂的间苯二酚衍生物
UA107360C2 (en) 2009-08-05 2014-12-25 Biogen Idec Inc Bicyclic aryl sphingosine 1-phosphate analogs
WO2011082400A2 (en) 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
CN101845043A (zh) 2010-01-15 2010-09-29 江苏省农药研究所股份有限公司 邻杂环甲酰苯胺类化合物及其合成方法和应用
WO2011085575A1 (zh) 2010-01-15 2011-07-21 江苏省农药研究所股份有限公司 邻杂环甲酰苯胺类化合物及其合成方法和应用
CN101747325A (zh) 2010-01-15 2010-06-23 江苏省农药研究所股份有限公司 邻杂环甲酰苯胺类化合物及其合成方法和应用
US20130109672A1 (en) 2010-04-29 2013-05-02 The United States Of America,As Represented By The Secretary, Department Of Health And Human Service Activators of human pyruvate kinase
TW201210597A (en) 2010-06-09 2012-03-16 Gilead Sciences Inc Inhibitors of hepatitis C virus
CA2804716A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
CA2818903C (en) 2010-12-14 2021-03-23 Electrophoretics Limited 5-(1,3-benzoxazol-2-yl)-4-(pyridin-4-yl)pyrimidin-2-amine and its use as a casein kinase 1delta inhibitor
EP2655334B1 (en) 2010-12-22 2018-10-03 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
PL220630B1 (pl) 2012-12-28 2015-11-30 Inst Immunologii I Terapii Doświadczalnej Pan Nowe sulfonamidowe pochodne izoksazolo[5,4-b]pirydyny o aktywności przeciwbakteryjnej, sposób ich wytwarzania oraz nowe zastosowanie 3-aminoizoksazolo[5,4-b]pirydyny
BR112015023397A2 (pt) 2013-03-15 2017-07-18 Genentech Inc benzoxazois substituídos e métodos de uso dos mesmos
WO2015102929A1 (en) 2013-12-30 2015-07-09 Novartis Ag Tricyclic sulfonamide derivatives
US10065945B2 (en) 2014-01-24 2018-09-04 Merck Sharp & Dohme Corp. Isoquinoline derivatives as MGAT2 inhibitors
GB201510019D0 (en) 2015-06-09 2015-07-22 Cancer Therapeutics Crc Pty Ltd Compounds
WO2017002120A1 (en) 2015-07-02 2017-01-05 Yeda Research And Development Co. Ltd. Selective inhibitors of senescent cells and uses thereof
WO2017098421A1 (en) 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Benzothiadiazine compounds
CN107098846B (zh) * 2016-02-26 2020-10-09 中国医学科学院药物研究所 N-酰基磺酰胺类FBPase抑制剂、其制备方法、药物组合物及用途
WO2018081167A1 (en) 2016-10-24 2018-05-03 Yumanity Therapeutics Compounds and uses thereof
US20220267260A1 (en) * 2016-11-29 2022-08-25 Epizyme, Inc. Compounds containing a sulfonic group as kat inhibitors
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
GB201810092D0 (en) * 2018-06-20 2018-08-08 Ctxt Pty Ltd Compounds
MD3986890T2 (ro) 2019-06-18 2024-04-30 Pfizer Derivați de benzizoxazolsulfonamide

Also Published As

Publication number Publication date
ES2969616T3 (es) 2024-05-21
JP7352662B2 (ja) 2023-09-28
CA3143666A1 (en) 2020-12-24
EP3986890A1 (en) 2022-04-27
PT3986890T (pt) 2024-01-17
HRP20231501T1 (hr) 2024-03-01
ECSP21091615A (es) 2022-01-31
AU2020296361A1 (en) 2022-01-06
CN114364672A (zh) 2022-04-15
LT3986890T (lt) 2023-12-11
HUE064683T2 (hu) 2024-04-28
EP3986890B1 (en) 2023-11-15
UY38752A (es) 2021-01-29
PL3986890T3 (pl) 2024-03-11
FI3986890T3 (fi) 2024-01-15
KR20220024671A (ko) 2022-03-03
JP2022537285A (ja) 2022-08-25
JP2023175821A (ja) 2023-12-12
RS64931B1 (sr) 2023-12-29
CO2021017504A2 (es) 2022-01-17
TWI787620B (zh) 2022-12-21
MD3986890T2 (ro) 2024-04-30
MX2021016085A (es) 2022-04-20
CA3143666C (en) 2024-06-11
TW202115048A (zh) 2021-04-16
SI3986890T1 (sl) 2024-03-29
US20200399258A1 (en) 2020-12-24
IL288802A (en) 2022-02-01
EP4299135A3 (en) 2024-02-28
EP4299135A2 (en) 2024-01-03
PE20220808A1 (es) 2022-05-20
US20230174522A1 (en) 2023-06-08
DK3986890T3 (da) 2023-12-18
CL2021003372A1 (es) 2022-10-07
WO2020254946A1 (en) 2020-12-24
AU2023274178A1 (en) 2024-02-15
BR112021025528A2 (pt) 2022-04-19
CN114364672B (zh) 2024-09-06
US11492346B2 (en) 2022-11-08

Similar Documents

Publication Publication Date Title
CR20210627A (es) Derivados de benzisoxazol sulfonimada
MX2023001379A (es) Derivados de piperidin-1-il-n-piridina-3-il-2-oxoacet amida utiles para el tratamiento de canceres deficientes en mtap y/o que acumulan mt a.
PH12021551529A1 (en) 3-carbonylamino-5-cyclopentyl-1h-pyrazole compounds having inhibitory activity on cdk2
MX2020011294A (es) Derivados de 2-amino-piridina o 2-amino-pirimidina como inhibidores de cinasa dependientes de ciclina.
MX2020011501A (es) Compuestos novedosos.
WO2020113213A3 (en) Cyclic pantetheine derivatives and uses thereof
EP4316591A3 (en) Oxysterols and methods of use thereof
MX2020009530A (es) Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa.
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
MX2022013401A (es) Compuestos de azalactama como inhibidores de hpk1.
MX2022004450A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1.
EA200601194A1 (ru) Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором
MX2023015139A (es) Inhibidores de mutacion de her2.
PH12021551232A1 (en) Haloallylamine compounds and application thereof
CR20220638A (es) Derivados de amidopirimidona
MX2021012491A (es) Agentes antiproliferativos para el tratamiento de la hipertensión arterial pulmonar.
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
TN2016000459A1 (en) Cycloalkyl-linked diheterocycle derivatives.
SA522431777B1 (ar) مشتقات ألفا -d- جالاكتو بيرانوسيد
MX2021003232A (es) Inhibidores de o-glicoproteina-2-acetamido-2-desoxi-3-d-glucopiran osidasa.
MX2023009954A (es) Compuestos de aminopirimidina y métodos de uso de estos.
MX2023010942A (es) Moduladores de sting (estimulador de genes de interferon).
MX2023008562A (es) Derivados de pirazolamida.
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
MX2021015727A (es) Derivados de piridin-3-ilo.